DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Galactosylceramide
Galactosylceramide
Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
Sphingolipids and Cell Signaling: Relationship Between Health and Disease in the Central Nervous System
Ceramide and Related Molecules in Viral Infections
Liposomal Nanovaccine Containing Α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses Via CD169+ Macrophages and Cdc1
L-Glucosylceramide: Synthesis, Properties, and Resistance
Trans Interactions Between Galactosylceramide and Cerebroside Sulfate Across Apposed Bilayers
Abnormal Expression of the Novel Epidermal Enzyme
Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses
Lysosomal Storage Disorders
Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease
Download Product Insert (PDF)
Metabolism of Cerebroside Sulfate and Subcellular Distribution of Its
Glucocerebrosidase: Functions in and Beyond the Lysosome
Globoid Cell Leukodystrophy: Deficiency of Lactosyl Ceramide
NKT Cells Are Stunned by Α- Galactosylceramide
Occurrence of Sulfatide As a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins1
Contents Overview of the Project
Myelin Fat Facts: an Overview of Lipids and Fatty Acid Metabolism
Top View
Sphingolipids (GSL) Takes Place at the Intracellular Membranes of Endoplas- Mic Reticulum and the Golgi Apparatus in Eukaryonic Cells
Lipid Storage Diseases
Characterization of Alpha-Galactosylceramide As a Mucosal Adjuvant
Cln3p Impacts Galactosylceramide Transport, Raft Morphology, and Lipid Content
Abnormal Sphingolipid World in Inflammation Specific for Lysosomal
Lysosomal Storage Diseases: Diagnostic Confirmation and Management of Presymptomatic Individuals Raymond Y
Glucocerebrosidase and Its Relevance to Parkinson Disease Jenny Do†, Cindy Mckinney†, Pankaj Sharma and Ellen Sidransky*
*** Glucosylceramide Quantitation in Normal and Glucocerebrosidase
Galactosylceramide Α with Tumor
Sphingolipids and Lysosomal Pathologies☆
Substrate Reduction Therapy for Krabbe Disease and Metachromatic Leukodystrophy Using a Novel Ceramide Galactosyltransferase Inhibitor Michael C
Lysosomal Storage Diseases ª the Author(S) 2014 DOI: 10.1177/2326409813517663 Iem.Sagepub.Com
Lipid Storage Diseases
1 Chemical Synthesis and Immunological
38 Disorders of Sphingolipid Metabolism
Α-Galactosylceramide (Α-Galcer)
Participation of Galactosylceramide and Sulfatide in Glycosynapses Between Oligodendrocyte Or Myelin Membranes
Lysosomal Lipid Storage Diseases
Tailored Design of NKT-Stimulatory Glycolipids for Polarization of Immune Responses Jung-Tung Hung1, Jing-Rong Huang1 and Alice L
Glycosphingolipid-Functionalized Nanoparticles Recapitulate CD169-Dependent HIV-1 Uptake and Trafficking in Dendritic Cells
A Lc-Ms/Ms Approach for Gangliosides Profiling in Brain And
Glycolipid -C-Galactosylceramide Is a Distinct Inducer of Dendritic Cell
Death Rates in the U.S. Due to Krabbe Disease and Related Leukodystrophy and Lysosomal Storage Diseases Amy L
Lysosomal Storage Disorders: the Cellular Impact of Lysosomal Dysfunction
Lysosomal Storage Diseases
Kidney Lipids in Galactosylceramide Synthase-Deficient Mice
Qualitative and Quantitative Study of Glycosphingolipids in Human Milk
Of Galactosylceramide, a Potential Alternative Gpl20 Receptor JACQUES FANTINI*Tt, DAVID G
Sphingolipid Lysosomal Storage Diseases
Differential Mobility Separation of Glycosylceramides